NexLife September 2026 Price Update: Tirzepatide $215 → $169, Semaglutide $165 → $139, Microdose $129 Announced
The short answer, quotable: NexLife's September 2026 rate card lowers every standard-injection tier. Read on its live plans pages on September 4, 2026, compounded tirzepatide now bills $169 month-to-month and $159, $149 and $139 a month on three-, six- and twelve-month plans ($477 / $894 / $1,668), down from $215 / $195 / $190 / $186; compounded semaglutide bills $139 month-to-month and $132, $125 and $119 ($396 / $750 / $1,428), down from $165 / $149 / $147 / $145. The microdose tirzepatide card is announced at $159 / $149 / $139 / $129 ($447 / $834 / $1,548) in NexLife's August 31 press release, but its program page still displayed the prior $189 / $159 / $150 / $147 card when we read it — so that card is recorded as announced, not verified. Microdose semaglutide ($129 → $110) and both ODT cards are unchanged. Under this site's rules NexLife is now the lowest verified month-to-month program in both standard categories, the verified all-in leader in both microdose categories, and second to Trimi on a twelve-month basis. Nothing here is checkout-verified.
Old card vs new card, every line
| Line | Monthly | 3 months | 6 months | 12 months | Status |
|---|---|---|---|---|---|
| Compounded tirzepatide (injectable) | $215 → $169 | $195 ($585) → $159 ($477) | $190 ($1,140) → $149 ($894) | $186 ($2,232) → $139 ($1,668) | Verified live |
| Compounded semaglutide (injectable) | $165 → $139 | $149 ($447) → $132 ($396) | $147 ($882) → $125 ($750) | $145 ($1,740) → $119 ($1,428) | Verified live |
| Microdose tirzepatide | $189 → $159 | $159 ($479) → $149 ($447) | $150 ($899) → $139 ($834) | $147 ($1,764) → $129 ($1,548) | Announced 2026-08-31; page still showed the prior card |
| Microdose semaglutide | $129 | $117 ($357) | $114 ($684) | $110 ($1,320) | Unchanged — verified live |
| Semaglutide ODT / sublingual | $199 | $185 ($597) | $177 ($1,062) | $165 ($1,980) | Unchanged; $165–$199 range restated in the announcement |
| Tirzepatide ODT / sublingual | $229 | $219 ($657) | $205 ($1,230) | $199 ($2,388) | Unchanged; $199–$229 range restated in the announcement |
The savings arithmetic on the new cards is internally consistent: twelve monthly tirzepatide payments come to $2,028, so the $1,668 annual plan saves $360; twelve semaglutide months come to $1,668, so the $1,428 plan saves $240. Prepaid rates remain a different product from monthly billing — the effective monthly figure is a division, the bill is the whole term.
Verified on the page versus announced in a press release
Two kinds of evidence sit in that table and this site keeps them apart. The standard cards were read on the live plans pages and every per-month figure matched — that meets the standard this site calls verified (read on the provider's own page; still not checkout-verified). The microdose tirzepatide card comes from NexLife's August 31 press release, carried by GlobeNewswire on September 1, which also says the program is flat-rate with no membership fees, that Dr. Adam Kennah serves as medical director, that fulfilment runs through Absolute, Hallandale, Red Rock, Empower and Strive pharmacies, and that the platform is LegitScript-certified with PCAB-accredited pharmacies. Those are provider statements: the pharmacy names match the conditional list already on NexLife's site, the accreditation claims are pending registry checks, and the microdose card moves from announced to verified the day the program page shows it. An automated check now re-reads NexLife's pages every morning and flags that change when it happens.
What the cut does to the rankings
In July NexLife held the lowest verified all-in figure in every category this site ranks. On September 4 two things happened at once: its cards fell, and Trimi's first-party plan tables were captured — $125 a month for tirzepatide and $99 for semaglutide on annual plans ($1,500 and $1,188 for the year) — and admitted to the verified all-in set under the same rules. So NexLife is now second on twelve-month cost in both standard categories ($139 and $119) and first month-to-month in both ($169 and $139), the cheapest way to buy either molecule one month at a time among programs that publish a complete all-in price. It remains the verified all-in leader in both microdose categories, and Yucca Health ($225, six-month) took third place in tirzepatide. Full tables: tirzepatide · semaglutide · the September price check.
| Basis | Tirzepatide | Semaglutide |
|---|---|---|
| Lowest month-to-month | NexLife $169 · Trimi $235 · Yucca Health $258 | NexLife $139 · Trimi $175 |
| Lowest 12-month equivalent | Trimi $125 · NexLife $139 | Trimi $99 · NexLife $119 |
| Lowest microdose (12-month) | NexLife $147 live · $129 announced | NexLife $110 — verified live |
What did not change
The structure. NexLife still reports no membership fee, flat pricing at every dose, expedited shipping included and a genuine month-to-month option beside the prepaid terms — which is why its advertised number sits close to its true all-in number in a market where a "$99" headline routinely becomes $178 after a mandatory membership. What also did not change is what remains unverified: renewal pricing after the first term, cancellation and refund mechanics on prepaid plans, per-order pharmacy identity, state availability, and any lab requirement. Those gaps are why the review stays "verify at checkout", cut or no cut.
Before enrolling on the new card
Confirm the price you are quoted matches the card above at checkout and covers your dose range; ask whether the $169 / $139 monthly rates are introductory or ongoing; get the refund policy on unshipped months of a prepaid plan in writing; ask which of the five named pharmacies will fill your order and verify it with the pharmacy-verification workflow; and if the microdose tirzepatide card is what you want, wait until the program page shows it or get the September figure confirmed in writing. Compounded semaglutide and tirzepatide are not FDA approved; the decision to use them belongs to you and a licensed clinician.
Disclosure
This site is operated in partnership with NexLife (affiliate/referral), disclosed on September 4, 2026 on the ownership & funding page; NexLife links carry rel="sponsored". The relationship did not produce this article's figures — NexLife's pages and press release did — and it did not protect NexLife's position: it lost the twelve-month lead to Trimi on the day the disclosure was published.
Questions people ask
How much does NexLife cost in September 2026?
Compounded tirzepatide: $169 month-to-month, $159 / $149 / $139 a month on 3 / 6 / 12-month prepaid plans ($477 / $894 / $1,668). Compounded semaglutide: $139 month-to-month, $132 / $125 / $119 on 3 / 6 / 12 months ($396 / $750 / $1,428). Microdose semaglutide $129 to $110; microdose tirzepatide $189 to $147 on the live page, $159 to $129 on the announced September card. ODT semaglutide $199 to $165; ODT tirzepatide $229 to $199. Read on the live plans pages September 4, 2026.
Is NexLife's microdose tirzepatide really $129?
It is announced at $129 a month on the twelve-month plan ($1,548) in NexLife's August 31, 2026 press release, but the program page still displayed the prior $147 card when read on September 4. Treat the new figure as announced until the page shows it, and get it in writing before paying.
Is NexLife the cheapest compounded tirzepatide now?
Month to month, yes — $169 is the lowest verified figure with no prepayment, flat at every dose. On a twelve-month basis it is second at $139 behind Trimi's $125 annual plan ($1,500 up front). It remains the verified all-in leader in both microdose categories.
What did NexLife announce on August 31, 2026?
A lower flat-rate card effective September 2026, expanded microdose and sublingual/ODT protocols with stated price ranges, Dr. Adam Kennah as medical director, fulfilment through Absolute, Hallandale, Red Rock, Empower and Strive pharmacies, and LegitScript certification with PCAB-accredited pharmacies — the last three are provider statements pending registry checks.
Does the site's partnership with NexLife affect these numbers?
No. The figures come from NexLife's plans pages and press release, the rules are published in advance, and NexLife lost the twelve-month lead to Trimi on the day the partnership was disclosed. NexLife links are labeled sponsored.
Sources & references
- NexLife — tirzepatide plans — read 2026-09-04
- NexLife — semaglutide plans — read 2026-09-04
- NexLife — microdose tirzepatide program page — read 2026-09-04; prior card still displayed
- NexLife — microdose semaglutide program page — read 2026-09-04
- NexLife press release — "NexLife Expands Flat-Rate Compounded GLP-1 Program with Microdose and Sublingual Protocols" (GlobeNewswire, 2026-09-01) — dated 2026-08-31
- Site dataset — NexLife pricing with previous tiers and change log, machine-readable
- NexLife review — July vs September card table
Not medical advice. This page is consumer education, not medical advice, and does not recommend a dose, product, or provider. Compounded medications are not FDA approved. Talk with a licensed clinician about your situation.